JP4388694B2 - 複数のアレル部位における増幅産物のゲノム型決定 - Google Patents
複数のアレル部位における増幅産物のゲノム型決定 Download PDFInfo
- Publication number
- JP4388694B2 JP4388694B2 JP2000530635A JP2000530635A JP4388694B2 JP 4388694 B2 JP4388694 B2 JP 4388694B2 JP 2000530635 A JP2000530635 A JP 2000530635A JP 2000530635 A JP2000530635 A JP 2000530635A JP 4388694 B2 JP4388694 B2 JP 4388694B2
- Authority
- JP
- Japan
- Prior art keywords
- fluorescent
- probe
- fluorescence
- probes
- allele
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003321 amplification Effects 0.000 title claims abstract description 116
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 116
- 238000003205 genotyping method Methods 0.000 title abstract description 15
- 108700028369 Alleles Proteins 0.000 title description 204
- 239000000523 sample Substances 0.000 claims abstract description 446
- 238000000034 method Methods 0.000 claims abstract description 119
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims abstract description 103
- 239000002751 oligonucleotide probe Substances 0.000 claims abstract description 103
- 101710163270 Nuclease Proteins 0.000 claims abstract description 81
- 238000002189 fluorescence spectrum Methods 0.000 claims abstract description 62
- 238000010791 quenching Methods 0.000 claims abstract description 58
- 238000006243 chemical reaction Methods 0.000 claims abstract description 47
- 230000000694 effects Effects 0.000 claims abstract description 32
- 108020004414 DNA Proteins 0.000 claims description 116
- 238000002844 melting Methods 0.000 claims description 55
- 230000008018 melting Effects 0.000 claims description 55
- 108091093088 Amplicon Proteins 0.000 claims description 49
- 230000002441 reversible effect Effects 0.000 claims description 47
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- 230000000171 quenching effect Effects 0.000 claims description 35
- 108091034117 Oligonucleotide Proteins 0.000 claims description 31
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 31
- 125000003729 nucleotide group Chemical group 0.000 claims description 30
- 239000002773 nucleotide Substances 0.000 claims description 29
- 239000011541 reaction mixture Substances 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 238000000137 annealing Methods 0.000 claims description 23
- 238000009396 hybridization Methods 0.000 claims description 13
- 108010010803 Gelatin Proteins 0.000 claims description 11
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 11
- 239000008273 gelatin Substances 0.000 claims description 11
- 229920000159 gelatin Polymers 0.000 claims description 11
- 235000019322 gelatine Nutrition 0.000 claims description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims description 11
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 11
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 11
- 238000012546 transfer Methods 0.000 claims description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 10
- 230000029087 digestion Effects 0.000 claims description 8
- 239000007983 Tris buffer Substances 0.000 claims description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 6
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 claims description 4
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims description 4
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 claims description 4
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 claims description 4
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 claims description 4
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 claims 2
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 abstract description 80
- 108020004707 nucleic acids Proteins 0.000 abstract description 78
- 102000039446 nucleic acids Human genes 0.000 abstract description 78
- 238000003556 assay Methods 0.000 description 98
- 238000003752 polymerase chain reaction Methods 0.000 description 34
- 238000001228 spectrum Methods 0.000 description 30
- 230000000295 complement effect Effects 0.000 description 28
- 102000007325 Amelogenin Human genes 0.000 description 26
- 108010007570 Amelogenin Proteins 0.000 description 26
- 239000000975 dye Substances 0.000 description 24
- 239000011159 matrix material Substances 0.000 description 21
- 108010037497 3'-nucleotidase Proteins 0.000 description 18
- 101150037123 APOE gene Proteins 0.000 description 17
- 108020004705 Codon Proteins 0.000 description 17
- 238000011160 research Methods 0.000 description 17
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 13
- 238000005457 optimization Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 9
- 239000010931 gold Substances 0.000 description 9
- 229910052737 gold Inorganic materials 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000002777 nucleoside Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000006073 displacement reaction Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108010006785 Taq Polymerase Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940104302 cytosine Drugs 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 150000003833 nucleoside derivatives Chemical class 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000013918 Apolipoproteins E Human genes 0.000 description 4
- 108010025628 Apolipoproteins E Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000022099 Alzheimer disease 2 Diseases 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000012864 cross contamination Methods 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 150000008298 phosphoramidates Chemical class 0.000 description 2
- -1 phosphoranilides Chemical class 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000001022 rhodamine dye Substances 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- WKKCYLSCLQVWFD-UHFFFAOYSA-N 1,2-dihydropyrimidin-4-amine Chemical compound N=C1NCNC=C1 WKKCYLSCLQVWFD-UHFFFAOYSA-N 0.000 description 1
- BGGCPIFVRJFAKF-UHFFFAOYSA-N 1-[4-(1,3-benzoxazol-2-yl)phenyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 BGGCPIFVRJFAKF-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- UKLNSYRWDXRTER-UHFFFAOYSA-N 7-isocyanato-3-phenylchromen-2-one Chemical compound O=C1OC2=CC(N=C=O)=CC=C2C=C1C1=CC=CC=C1 UKLNSYRWDXRTER-UHFFFAOYSA-N 0.000 description 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
- NLSUMBWPPJUVST-UHFFFAOYSA-N 9-isothiocyanatoacridine Chemical compound C1=CC=C2C(N=C=S)=C(C=CC=C3)C3=NC2=C1 NLSUMBWPPJUVST-UHFFFAOYSA-N 0.000 description 1
- 241001502050 Acis Species 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 150000005002 naphthylamines Chemical class 0.000 description 1
- 125000005184 naphthylamino group Chemical group C1(=CC=CC2=CC=CC=C12)N* 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000001018 xanthene dye Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Amplifiers (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1859598A | 1998-02-04 | 1998-02-04 | |
| US09/018,595 | 1998-02-04 | ||
| PCT/US1999/000499 WO1999040226A2 (en) | 1998-02-04 | 1999-01-08 | Determination of a genotype of an amplification product at multiple allelic sites |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002502615A JP2002502615A (ja) | 2002-01-29 |
| JP2002502615A5 JP2002502615A5 (enExample) | 2006-02-16 |
| JP4388694B2 true JP4388694B2 (ja) | 2009-12-24 |
Family
ID=21788757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000530635A Expired - Lifetime JP4388694B2 (ja) | 1998-02-04 | 1999-01-08 | 複数のアレル部位における増幅産物のゲノム型決定 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US6154707A (enExample) |
| EP (1) | EP1053348B1 (enExample) |
| JP (1) | JP4388694B2 (enExample) |
| AT (1) | ATE469982T1 (enExample) |
| AU (1) | AU758463B2 (enExample) |
| CA (1) | CA2318880C (enExample) |
| DE (1) | DE69942444D1 (enExample) |
| WO (1) | WO1999040226A2 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2255599C (en) | 1996-04-25 | 2006-09-05 | Bioarray Solutions, Llc | Light-controlled electrokinetic assembly of particles near surfaces |
| AU1232099A (en) * | 1997-11-04 | 1999-05-24 | Roche Diagnostics Gmbh | Specific and sensitive method for detecting nucleic acids |
| CA2318880C (en) * | 1998-02-04 | 2010-07-27 | Perkin-Elmer Corporation | Determination of a genotype of an amplification product at multiple allelic sites |
| CA2387306C (en) * | 1999-10-22 | 2010-04-27 | The Public Health Research Institute Of The City Of New York, Inc. | Assays for short sequence variants |
| US7585632B2 (en) * | 1999-10-29 | 2009-09-08 | Hologic, Inc. | Compositions and methods for the detection of a nucleic acid using a cleavage reaction |
| US6660845B1 (en) | 1999-11-23 | 2003-12-09 | Epoch Biosciences, Inc. | Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof |
| US6727356B1 (en) | 1999-12-08 | 2004-04-27 | Epoch Pharmaceuticals, Inc. | Fluorescent quenching detection reagents and methods |
| US20040081959A9 (en) | 1999-12-08 | 2004-04-29 | Epoch Biosciences, Inc. | Fluorescent quenching detection reagents and methods |
| JP2001299392A (ja) * | 2000-04-25 | 2001-10-30 | Otsuka Pharmaceut Co Ltd | Ｃａｔｃｈ２２症候群検出方法 |
| US7435541B2 (en) | 2000-05-23 | 2008-10-14 | Sequenom, Inc. | Restriction enzyme genotyping |
| JP2004511210A (ja) * | 2000-05-23 | 2004-04-15 | バリアジェニックス インコーポレーテッド | 配列変動を検出する、ｄｎａを遺伝分析するための方法 |
| ATE319087T1 (de) | 2000-06-21 | 2006-03-15 | Bioarray Solutions Ltd | Multianalytische molekularanalyse durch verwendung anwendungsspezifischer zufallspartikelarrays |
| US9709559B2 (en) | 2000-06-21 | 2017-07-18 | Bioarray Solutions, Ltd. | Multianalyte molecular analysis using application-specific random particle arrays |
| GB0016516D0 (en) * | 2000-07-06 | 2000-08-23 | Owen Mumford Ltd | Improvements relating to needle protection devices |
| US7267945B2 (en) * | 2001-03-26 | 2007-09-11 | Applera Corporation | Methods of determining the presence of polynucleotides employing amplification |
| US20030143554A1 (en) * | 2001-03-31 | 2003-07-31 | Berres Mark E. | Method of genotyping by determination of allele copy number |
| US7262063B2 (en) | 2001-06-21 | 2007-08-28 | Bio Array Solutions, Ltd. | Directed assembly of functional heterostructures |
| NZ530602A (en) * | 2001-06-28 | 2006-02-24 | Chiron Corp | Methods for detecting human parvovirus B19 in a biological sample comprising hybridising primers with a target sequence, the presence of which indicates the presence of the virus |
| JP4377689B2 (ja) | 2001-10-15 | 2009-12-02 | バイオアレイ ソリューションズ リミテッド | 同時尋問及び酵素仲介検出による多型遺伝子座の複合分析 |
| EP1439222A1 (en) * | 2001-10-26 | 2004-07-21 | Matsushita Electric Industrial Co., Ltd. | Method of detecting target nucleic acid and nucleic acid probe |
| US7732138B2 (en) * | 2001-11-07 | 2010-06-08 | Diagcor Bioscience Incorporation Limited | Rapid genotyping analysis and the device thereof |
| US20050079493A1 (en) * | 2002-11-09 | 2005-04-14 | Tam Joseph Wing On | DNA fingerprinting using allelic specific oligonucleotide reversed dot blot (ASO-RDB) flow through hybridization process and device |
| US20110111389A1 (en) | 2001-11-07 | 2011-05-12 | Diagcor Bioscience Incorporation Limited | Rapid genotyping analysis for human papillomavirus and the device thereof |
| AU2003216489A1 (en) * | 2002-03-05 | 2003-09-22 | M.C.W Research Foundation, Inc. | Methods and compositions for pharmacological and toxicological evaluation of test agents |
| US7176002B2 (en) * | 2002-05-16 | 2007-02-13 | Applera Corporation | Universal-tagged oligonucleotide primers and methods of use |
| US20070059690A1 (en) * | 2002-05-31 | 2007-03-15 | Amirul Islam | "Met/fret based method of target nucleic acid detection whereby the donor/acceptor moieties are on complementary strands" |
| AU2003240295A1 (en) * | 2002-06-20 | 2004-01-06 | Vision Biosystems Limited | Biological reaction apparatus with draining mechanism |
| AU2003901871A0 (en) * | 2003-03-31 | 2003-05-08 | Vision Biosystems Limited | A method and apparatus for fluid dispensation, preparation and dilation |
| US7252940B2 (en) * | 2002-08-21 | 2007-08-07 | Epoch Biosciences, Inc. | Abasic site endonuclease assay |
| WO2004047007A1 (en) | 2002-11-15 | 2004-06-03 | Bioarray Solutions, Ltd. | Analysis, secure access to, and transmission of array images |
| US20050066276A1 (en) * | 2002-12-13 | 2005-03-24 | Moore Helen M. | Methods for identifying, viewing, and analyzing syntenic and orthologous genomic regions between two or more species |
| US7851150B2 (en) * | 2002-12-18 | 2010-12-14 | Third Wave Technologies, Inc. | Detection of small nucleic acids |
| CN101405404A (zh) | 2002-12-31 | 2009-04-08 | 迈特默菲公司 | 用于推断牛的性状的组合物、方法和系统 |
| US7858301B2 (en) * | 2003-05-07 | 2010-12-28 | Bioarray Solutions, Ltd. | Method of probe design for nucleic acid analysis by multiplexed hybridization |
| ATE553216T1 (de) * | 2003-06-20 | 2012-04-15 | Exiqon As | Sonden, bibliotheken und kits zur analyse von nukleinsäuregemischen und verfahren zu deren konstruktion |
| US20050038776A1 (en) * | 2003-08-15 | 2005-02-17 | Ramin Cyrus | Information system for biological and life sciences research |
| WO2005029705A2 (en) | 2003-09-18 | 2005-03-31 | Bioarray Solutions, Ltd. | Number coding for identification of subtypes of coded types of solid phase carriers |
| US20050221357A1 (en) * | 2003-09-19 | 2005-10-06 | Mark Shannon | Normalization of gene expression data |
| US7417726B2 (en) * | 2003-09-19 | 2008-08-26 | Applied Biosystems Inc. | Normalization of data using controls |
| EP1664722B1 (en) | 2003-09-22 | 2011-11-02 | Bioarray Solutions Ltd | Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules |
| US7332280B2 (en) * | 2003-10-14 | 2008-02-19 | Ronald Levy | Classification of patients having diffuse large B-cell lymphoma based upon gene expression |
| WO2005042763A2 (en) | 2003-10-28 | 2005-05-12 | Bioarray Solutions Ltd. | Optimization of gene expression analysis using immobilized capture probes |
| US7049077B2 (en) | 2003-10-29 | 2006-05-23 | Bioarray Solutions Ltd. | Multiplexed nucleic acid analysis by fragmentation of double-stranded DNA |
| WO2005049849A2 (en) | 2003-11-14 | 2005-06-02 | Integrated Dna Technologies, Inc. | Fluorescence quenching azo dyes, their methods of preparation and use |
| EP1561823A1 (de) * | 2004-02-04 | 2005-08-10 | Biotez Berlin-Buch GmbH | Verfahren zum Nachweis von Einzelnukleotid-polymorphismen (SNP) in Genen des Arzneimittelmetabolismus und Testkit zur Durchführung des Verfahrens |
| US20050255485A1 (en) * | 2004-05-14 | 2005-11-17 | Livak Kenneth J | Detection of gene duplications |
| US7575863B2 (en) * | 2004-05-28 | 2009-08-18 | Applied Biosystems, Llc | Methods, compositions, and kits comprising linker probes for quantifying polynucleotides |
| US7848889B2 (en) | 2004-08-02 | 2010-12-07 | Bioarray Solutions, Ltd. | Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification |
| US7642055B2 (en) * | 2004-09-21 | 2010-01-05 | Applied Biosystems, Llc | Two-color real-time/end-point quantitation of microRNAs (miRNAs) |
| US20060111915A1 (en) * | 2004-11-23 | 2006-05-25 | Applera Corporation | Hypothesis generation |
| US8084260B2 (en) * | 2004-11-24 | 2011-12-27 | Applied Biosystems, Llc | Spectral calibration method and system for multiple instruments |
| EP1829964A4 (en) * | 2004-12-08 | 2009-03-04 | Takeshi Yamamoto | METHOD OF STUDYING A SEQUENCE OF A GENE |
| US20060166238A1 (en) * | 2004-12-22 | 2006-07-27 | Ramsing Niels B | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same |
| CA2601554A1 (en) | 2005-05-20 | 2006-11-30 | Integrated Dna Technologies, Inc. | Compounds and methods for labeling oligonucleotides |
| US8486629B2 (en) | 2005-06-01 | 2013-07-16 | Bioarray Solutions, Ltd. | Creation of functionalized microparticle libraries by oligonucleotide ligation or elongation |
| EP2477029A1 (en) | 2005-06-02 | 2012-07-18 | Fluidigm Corporation | Analysis using microfluidic partitioning devices |
| WO2007024800A2 (en) * | 2005-08-22 | 2007-03-01 | Applera Corporation | Device and method for making discrete volumes of a first fluid in contact with a second fluid, which are immiscible with each other |
| WO2007147074A2 (en) | 2006-06-14 | 2007-12-21 | Living Microsystems, Inc. | Use of highly parallel snp genotyping for fetal diagnosis |
| CN101675169B (zh) * | 2006-06-14 | 2018-01-02 | 维里纳塔健康公司 | 使用样品拆分和dna标签进行稀有细胞分析 |
| WO2008111990A1 (en) * | 2006-06-14 | 2008-09-18 | Cellpoint Diagnostics, Inc. | Rare cell analysis using sample splitting and dna tags |
| EP2589668A1 (en) | 2006-06-14 | 2013-05-08 | Verinata Health, Inc | Rare cell analysis using sample splitting and DNA tags |
| US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
| US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
| EP1911852B1 (en) * | 2006-10-12 | 2009-07-29 | Bio-Rad Pasteur | Double-stranded probes for the fluorescent detection of nucleic acids |
| DE102007013099A1 (de) | 2007-03-14 | 2008-09-18 | Aj Innuscreen Gmbh | Verfahren und Testkit zum schnellen Nachweis spezifischer Nukleinsäuresequenzen, insbesondere zum Nachweis von Mutationen oder SNP's |
| EP2336358A1 (en) * | 2008-05-06 | 2011-06-22 | QIAGEN GmbH | Simultaneous detection of multiple nucleic acid sequences in a reaction |
| CA2726850C (en) * | 2008-06-13 | 2015-06-02 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| US20090312196A1 (en) * | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| US8383346B2 (en) * | 2008-06-13 | 2013-02-26 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
| CA2737643C (en) | 2008-09-20 | 2020-10-06 | Hei-Mun Fan | Noninvasive diagnosis of fetal aneuploidy by sequencing |
| WO2010120800A1 (en) * | 2009-04-13 | 2010-10-21 | Canon U.S. Life Sciences, Inc. | A rapid method of pattern recognition, machine learning, and automated genotype classification through correlation analysis of dynamic signals |
| US20110312503A1 (en) | 2010-01-23 | 2011-12-22 | Artemis Health, Inc. | Methods of fetal abnormality detection |
| US8916345B2 (en) | 2010-03-26 | 2014-12-23 | Integrated Dna Technologies, Inc. | Methods for enhancing nucleic acid hybridization |
| US9506057B2 (en) | 2010-03-26 | 2016-11-29 | Integrated Dna Technologies, Inc. | Modifications for antisense compounds |
| EP2896696B1 (en) | 2010-09-07 | 2017-12-27 | Integrated Dna Technologies, Inc. | Modifications for antisense compounds |
| US20120083035A1 (en) | 2010-09-30 | 2012-04-05 | Dharmacon, Inc. | Modified Cell Lines for Increasing Lentiviral Titers |
| US9617588B2 (en) | 2010-10-05 | 2017-04-11 | Thermo Fisher Scientific Baltics Uab | Enzyme mixture |
| CA2874343C (en) | 2012-05-21 | 2021-11-09 | Fluidigm Corporation | Single-particle analysis of particle populations |
| US20170292144A1 (en) * | 2016-04-06 | 2017-10-12 | Life Technologies Corporation | Compositions, methods, and kits for synthesis and detection of nucleic acids |
| JP6846636B2 (ja) * | 2017-02-28 | 2021-03-24 | パナソニックＩｐマネジメント株式会社 | 核酸検出用オリゴヌクレオチド |
| WO2022155397A1 (en) * | 2021-01-15 | 2022-07-21 | Nuprobe Usa, Inc. | Cycle multiplexing for highly multiplexed quantitative pcr |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075216A (en) * | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
| JP3392863B2 (ja) * | 1990-07-24 | 2003-03-31 | エフ．ホフマン ― ラ ロシュ アーゲー | 修飾核酸塩基を使用するインビトロ核酸増幅における非特異的増幅の低減 |
| US5210015A (en) * | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5403707A (en) * | 1993-05-14 | 1995-04-04 | Eastman Kodak Company | Diagnostic compositions, elements, methods and test kits for amplification and detection of retroviral DNA using primers having matched melting temperatures |
| US5538848A (en) * | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5834181A (en) * | 1994-07-28 | 1998-11-10 | Genzyme Corporation | High throughput screening method for sequences or genetic alterations in nucleic acids |
| CA2209080C (en) * | 1994-12-30 | 2008-07-29 | Georgetown University | Fluorometric assay for detecting nucleic acid cleavage |
| DE19524579C2 (de) * | 1995-07-06 | 1997-12-18 | Daimler Benz Ag | Transformator als Strombegrenzer |
| US5792610A (en) * | 1996-05-01 | 1998-08-11 | Biorad Laboratories, Inc. | Method for conducting multiparametric fluorescence in situ hybridization |
| US5759781A (en) * | 1995-12-22 | 1998-06-02 | Yale University | Multiparametric fluorescence in situ hybridization |
| CA2252048C (en) * | 1996-04-12 | 2008-03-11 | The Public Health Research Institute Of The City Of New York, Inc. | Detection probes, kits and assays |
| US6015667A (en) * | 1996-06-03 | 2000-01-18 | The Perkin-Emer Corporation | Multicomponent analysis method including the determination of a statistical confidence interval |
| US5736333A (en) * | 1996-06-04 | 1998-04-07 | The Perkin-Elmer Corporation | Passive internal references for the detection of nucleic acid amplification products |
| CA2318880C (en) | 1998-02-04 | 2010-07-27 | Perkin-Elmer Corporation | Determination of a genotype of an amplification product at multiple allelic sites |
| US5952202A (en) * | 1998-03-26 | 1999-09-14 | The Perkin Elmer Corporation | Methods using exogenous, internal controls and analogue blocks during nucleic acid amplification |
-
1999
- 1999-01-08 CA CA2318880A patent/CA2318880C/en not_active Expired - Fee Related
- 1999-01-08 WO PCT/US1999/000499 patent/WO1999040226A2/en not_active Ceased
- 1999-01-08 EP EP99903026A patent/EP1053348B1/en not_active Expired - Lifetime
- 1999-01-08 AT AT99903026T patent/ATE469982T1/de not_active IP Right Cessation
- 1999-01-08 AU AU23144/99A patent/AU758463B2/en not_active Ceased
- 1999-01-08 JP JP2000530635A patent/JP4388694B2/ja not_active Expired - Lifetime
- 1999-01-08 DE DE69942444T patent/DE69942444D1/de not_active Expired - Lifetime
- 1999-06-03 US US09/324,709 patent/US6154707A/en not_active Expired - Lifetime
-
2002
- 2002-03-21 US US10/104,774 patent/US6884583B2/en not_active Expired - Lifetime
-
2003
- 2003-06-04 US US10/455,150 patent/US7132239B2/en not_active Expired - Fee Related
-
2006
- 2006-11-03 US US11/592,716 patent/US20080187913A1/en not_active Abandoned
-
2009
- 2009-11-13 US US12/618,686 patent/US20120053069A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1053348B1 (en) | 2010-06-02 |
| DE69942444D1 (de) | 2010-07-15 |
| ATE469982T1 (de) | 2010-06-15 |
| US7132239B2 (en) | 2006-11-07 |
| AU2314499A (en) | 1999-08-23 |
| EP1053348A2 (en) | 2000-11-22 |
| WO1999040226A2 (en) | 1999-08-12 |
| CA2318880A1 (en) | 1999-08-12 |
| CA2318880C (en) | 2010-07-27 |
| US20120053069A1 (en) | 2012-03-01 |
| WO1999040226A3 (en) | 2000-08-17 |
| US6154707A (en) | 2000-11-28 |
| JP2002502615A (ja) | 2002-01-29 |
| US20080187913A1 (en) | 2008-08-07 |
| US6884583B2 (en) | 2005-04-26 |
| AU758463B2 (en) | 2003-03-20 |
| US20040053302A1 (en) | 2004-03-18 |
| US20020164630A1 (en) | 2002-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4388694B2 (ja) | 複数のアレル部位における増幅産物のゲノム型決定 | |
| US6270967B1 (en) | Method for detecting a nucleic acid base sequence | |
| US7348141B2 (en) | Hybridization beacon and method of rapid sequence detection and discrimination | |
| US7998673B2 (en) | Hybridisation beacon and method of rapid sequence detection and discrimination | |
| Mhlanga et al. | Using molecular beacons to detect single-nucleotide polymorphisms with real-time PCR | |
| US9273350B2 (en) | Methods and primers for detecting target nucleic acid sequences | |
| EP1061135B1 (en) | Methods and oligonucleotides for detecting nucleic acid sequence variations | |
| US7846657B2 (en) | Detection of target nucleotide sequences using ligation assays with improved oligonucleotide probe pairs | |
| AU2001242634A1 (en) | Hybridisation beacon and method of rapid sequence detection and discrimination | |
| JP2002530120A (ja) | 核酸を検出するためのドナー分子およびアクセプター分子を利用するプライマー伸長方法 | |
| GB2312747A (en) | Primers with non-complementary tails for detection of diagnostic base sequences | |
| JP2006515982A (ja) | 核酸配列変異を検出する方法 | |
| ABBASZADEGAN et al. | Automated detection of prevalent mutations in BRCA1 and BRCA2 genes, using a fluorogenic PCR allelic discrimination assay | |
| AU2003204856B2 (en) | Determination of a Genotype of an Amplification Product at Multiple Allelic Sites | |
| AU2007201863A1 (en) | Determination of a genotype of an amplification product at multiple allelic sites | |
| EP1061134A2 (en) | Oligonucleotides for amplification and detection of hemochromatosis genes | |
| JP5504676B2 (ja) | 遺伝子型の識別方法 | |
| EP1400597A1 (en) | Oligonucleotides for amplification and detection of hemochromatosis gene | |
| ZA200207652B (en) | Hybridisation beacon and method of rapid sequence detection and discrimination. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051219 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090216 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090518 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090525 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090525 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20090618 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090817 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090825 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090917 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091005 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121009 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131009 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |